Dilated Cardiomyopathy Therapeutics Market

Industry Outlook

The dilated cardiomyopathy therapeutics market is set to reach US$ xx Mn by 2026 from US$ xx Mn in 2017, featuring magnificent growth at a compounded annual growth rate (CAGR) of 4.7% during the forecast period from 2018 to 2026. As per the latest research citations of the World Health Organization (WHO), annually, 17.9 million people die throughout the globe from cardiovascular diseases, which is equivalent to 31% of all global deaths. Factors responsible for congestive heart failure include a sedentary lifestyle, obesity, an unhealthy lifestyle, and congenital heart complications.

Pharmaceutical companies are striving earnestly to manufacture drugs with the fewest possible side effects and the desired therapeutic efficacy. Drugs in Phase III clinical trials showing promising results are enalapril orodispersible minitablets (Ethicare GmbH), ARRY-371797 (Array BioPharma), and ixCELL-DCM (Vericel Corporation).

Market Synopsis

Excellent clinical outcomes and satisfactory patient compliance make this drug class the most viable treatment option for dilated cardiomyopathy.

In the current scenario, drug classes are reigning in the treatment segment of the dilated cardiomyopathy therapeutics market. The parameters responsible for the growth of this drug class are the increasing number of patients diagnosed with congestive heart failure. Moreover, excellent clinical outcomes and satisfactory patient compliance make this drug class the most viable option for the treatment of dilated cardiomyopathy. Angiotensin-converting enzyme inhibitors (ACE inhibitors) are considered the first line of drug therapy due to their positive clinical effects, such as relaxing heart muscles and promoting blood flow. Angiotensin receptor blockers are given with diuretics to patients who do not tolerate ACE inhibitors. They help regulate the blood flow by widening blood vessels and reducing the fluid in the lungs and kidneys. Beta-blockers and anticoagulants are prescribed to reduce the pressure on the heart valves and prevent blood clotting in the heart chambers due to the inability of the weakened left ventricular muscles to pump blood. Implantable devices are gaining traction owing to the side effects associated with the drug class and the long-term benefit provided by devices such as heart pumps, biventricular pacemakers, and implantable cardioverter-defibrillators.

The increasing prevalence of congestive heart failure drives the growth of the dilated cardiomyopathy therapeutics market in North America.

North America is currently leading the geography segment for the dilated cardiomyopathy therapeutics market owing to factors such as the rising prevalence of congestive heart failure. According to the facts presented by the Centers for Disease Control and Prevention (CDC) in the United States, approximately 610,000 people die of heart disease annually. The existence of a well-developed healthcare infrastructure and an affordable reimbursement scenario drive the dilated cardiomyopathy market’s growth in North America. As per the latest research citations of the European Heart Network (EHN), every year, 3.9 million people die in Europe, amounting to 45% of all deaths caused in the region. The domicile of major players such as Merck & Co., Inc., GlaxoSmithKline Plc, and t2cure GmbH, etc., propels market growth in the European Union region. Asia Pacific will register outstanding growth during the forecast period on account of the rising prevalence of congenital heart diseases, a favorable regulatory scenario, and growing medical tourism due to affordable treatment costs. Latin America, the Middle East, and Africa serve as potential markets to promote business expansion opportunities by establishing subsidiaries and retail outlets for major players providing treatment options for dilated cardiomyopathy.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

Market estimation and the compounded annual growth rate were determined by studying the latest market trends prevalent in the dilated cardiomyopathy therapeutics market. The market is divided into two sections: treatment and region.

Pharmaceutical companies spearheading the dilated cardiomyopathy therapeutics market are Aastrom Biosciences, Capricor Therapeutics, GlaxoSmithKline Plc, Johnson & Johnson, Kasiak Research Pvt. Ltd., Merck & Co., Inc., MyoKardia, Pfizer, Inc., t2cure GmbH, Teva Pharmaceutical Industries, and ZensunSci & Tech.

Key questions are answered in this report.

• What are the organic and inorganic market growth strategies employed to determine the compounded annual growth rate and market estimation?
• Which pharmaceutical and medical device companies are engaged to provide treatment options for dilated cardiomyopathy?
• What are the DROs associated with the dilated cardiomyopathy therapeutics market?
• What is the disease etiology of dilated cardiomyopathy and the treatment regimen adopted by physicians throughout the globe?
• Which is the leading and fastest-growing treatment segment for the dilated cardiomyopathy therapeutics market?
• Which is the leading and fastest-growing regional segment for the dilated cardiomyopathy therapeutics market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global DCT Market Portraiture
2.2. Global DCT Market, by Treatment, 2017 (US$ Mn)
2.3. Global DCT Market, by Geography, 2017 (US$ Mn)

Chapter 3. Dilated Cardiomyopathy Therapeutics (DCT) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global DCT Market, by Key Players, 2017

Chapter 4. Global Dilated Cardiomyopathy Therapeutics (DCT) Market, by Treatment
4.1. Overview
4.2. Drug Class
4.2.1. Angiotensin II Receptor Blockers
4.2.2. Angiotensin-Converting Enzyme (ACE) Inhibitors
4.2.3. Beta Blockers
4.2.4. Anticoagulants
4.2.5. Digitalis
4.2.6. Diuretics
4.3. Implantable Device
4.3.1. Heart Pumps
4.3.2. Biventricular Pacemakers
4.3.3. Implantable Cardioverter-Defibrillators
4.4. Pipeline Analysis
4.4.1. Phase III Drugs
4.4.1.1. Enalapril Orodispersible Minitablet
4.4.1.2. ARRY-371797
4.4.1.3. ixCELL-DCM
4.4.2. Tabular Representation of Drug Pipeline in Phase II and I

Chapter 5. Global Dilated Cardiomyopathy Therapeutics (DCT) Market, by Geography
5.1. Overview
5.2. North America DCT Market Analysis, 2016 – 2026
5.2.1. North America DCT Market, by Treatment, 2016 – 2026 (US$ Mn)
5.2.2. North America DCT Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe DCT Market Analysis, 2016 – 2026
5.3.1. Europe DCT Market, by Treatment, 2016 – 2026 (US$ Mn)
5.3.2. Europe DCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific DCT Market Analysis, 2016 – 2026
5.4.1. Asia Pacific DCT Market, by Treatment, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific DCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America DCT Market Analysis, 2016 – 2026
5.5.1. Latin America DCT Market, by Treatment, 2016 – 2026 (US$ Mn)
5.5.2. Latin America DCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East and Africa DCT Market Analysis, 2016 – 2026
5.6.1. MEA DCT Market, by Treatment, 2016 – 2026 (US$ Mn)
5.6.2. MEA DCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Aastrom Biosciences
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Treatment Portfolio
6.1.4. News Coverage
6.2. Capricor Therapeutics
6.3. GlaxoSmithKline plc.
6.4. Johnson and Johnson
6.5. Kasiak Research Pvt. Ltd.
6.6. Merck & Co., Inc.
6.7. MyoKardia
6.8. Pfizer Inc.
6.9. t2cure GmbH.
6.10. Teva Pharmaceutical Industries
6.11. ZensunSci & tech.

List of Figures

FIG. 1 Dilated Cardiomyopathy Therapeutics (DCT) Market: Research Methodology
FIG. 2 DCT Market Segmentation
FIG. 3 Global DCT Market, by Treatment, 2017 (US$ Mn)
FIG. 4 Global DCT Market, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2017
FIG. 6 Competitive Analysis: Global DCT Market, by Key Players, 2017
FIG. 7 Global Angiotensin II Receptor Blockers Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 8 Global ACE Inhibitors Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 9 Global Beta Blockers Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 10 Global Anticoagulants Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 11 Global Digitalis Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 12 Global Diuretics Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 13 Global Heart Pumps Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 14 Global Biventricular Pacemakers Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 15 Global Implantable Cardioverter-Defibrillators Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 16 U.S. DCT Market, 2016 – 2026 (US$ Mn)
FIG. 17 Canada DCT Market, 2016 – 2026 (US$ Mn)
FIG. 18 U.K. DCT Market, 2016 – 2026 (US$ Mn)
FIG. 19 Germany DCT Market, 2016 – 2026 (US$ Mn)
FIG. 20 Rest of Europe DCT Market, 2016 – 2026 (US$ Mn)
FIG. 21 China DCT Market, 2016 – 2026 (US$ Mn)
FIG. 22 Japan DCT Market, 2016 – 2026 (US$ Mn)
FIG. 23 Rest of Asia Pacific DCT Market, 2016 – 2026 (US$ Mn)
FIG. 24 Brazil DCT Market, 2016 – 2026 (US$ Mn)
FIG. 25 Mexico DCT Market, 2016 – 2026 (US$ Mn)
FIG. 26 Rest of Latin America DCT Market, 2016 – 2026 (US$ Mn)
FIG. 27 GCC DCT Market, 2016 – 2026 (US$ Mn)
FIG. 28 Rest of MEA DCT Market, 2016 – 2026 (US$ Mn)

List of Tables

TABLE 1 Global DCT Market (DCT) Market Portraiture
TABLE 2 Global DCT Market Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 3 Global Drug Class Market for DCT Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 4 Global Implantable Device Market for DCT Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 5 Global DCT Market Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 6 North America DCT Market Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 7 North America DCT Market Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 8 Europe DCT Market Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 9 Europe DCT Market Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 10 Asia Pacific DCT Market Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 11 Asia Pacific DCT Market Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Latin America DCT Market Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 13 Latin America DCT Market Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 Middle East and Africa DCT Market Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 15 Middle East and Africa DCT Market Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 16 Aastrom Biosciences: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 17 Capricor Therapeutics: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 18 GlaxoSmithkline Plc.: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 19 Johnson and Johnson: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 20 Kasiak Research Pvt. Ltd.: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 21 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 22 Myokardia: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 23 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 24 T2cure GmbH: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 25 Teva Pharmaceuticals Industries: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 26 ZensunSci & tech.: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)